

Atrial fibrillation in The Tromsø Study 1994-2007

**Risk factors, occurrence and
gender differences**

Audhild Nyrnes
Faculty of Health Sciences
Department of Community Medicine
UiT The Arctic University of Norway

A dissertation for the degree of
Philosophiae Doctor

2015

Acknowledgements

First of all I am grateful to the Department of Community Medicine for providing me with excellent study facilities and access to the Tromsø Study. I feel privileged to have had the opportunity to spend some years at the Department, which provides a stimulating environment for PhD students in the field of epidemiological research. I also want to thank the people of Tromsø who participated and made this study possible. Thank you to the previous and present leaders of the Department of Geriatrics at the University Hospital of North Norway, Sigurd Sparr, Torgeir A. Engstad and Elena Kamycheva, who provided me with study leaves.

It all started as a break from my clinical work at the hospital when I spent some months as a case detective in the hospital files, searching for and adjudicating cardiovascular endpoints in the Tromsø Study. I really enjoyed that work. I am still very surprised to find myself as a researcher having written a thesis in epidemiology. That was not part of my plan at that time. My friend and main supervisor Maja-Lisa Løchen and my co supervisors Inger Njølstad and Ellisiv B. Mathiesen somehow managed to persuade me to start this marathon work. I have always met support, encouragement and constructive criticism from them. Thank you for your patience and for believing in me and my work. Tom Wilsgaard and the late Egil Arnesen gave me most valuable advice on statistics and SPSS. The help from my co-authors, the late Ingrid Toft in particular, but also from John-Bjarne Hanssen, Tove Skjelbakken and Lone Jørgensen is highly appreciated.

Financially, I was supported by a grant from the Norwegian ExtraFoundation for Health and Rehabilitation through EXTRA funds in collaboration with the Norwegian Heart and Lung Patient Organization. Simon Fougner Hartmann's Family Foundation and the Norwegian Health Association provided additional support.

During the long-lasting process of finishing this thesis, I especially want to thank Trine Magnus who provided invaluable advice and support.

Maja-Lisa always stood by, stubbornly enthusiastic and cheering! She is also a highly qualified secretary.

Finally, warm thanks to my dear close and extended family and my friends.

Tromsø, July 2015

Audhild

The diehard epidemiologist would perform complex statistical adjustments and modelling, but the cynic would argue that mathematical formulae can never fully account for all biological diversity and pathophysiology.

G.Y.Lip, G.I.Varughese, International Journal of Cardiology 2005; 105(3): 319-321

Contents

Acknowledgements

Summary

Sammendrag

List of papers

Abbreviations

1. Introduction/background

- 1.1 What is atrial fibrillation (AF)?
 - 1.1.1 Classification
 - 1.1.2. Pathogenesis/pathophysiology
- 1.2 What are the clinical implications of AF?
- 1.3 Epidemiology of AF
 - 1.3.1 Prevalence
 - 1.3.2 Incidence
 - 1.3.3 Increasing numbers
 - 1.3.4 Gender differences

2. Risk factors

- 2.1 Genetic factors
- 2.2 Cardiovascular, life style related and other risk factors
- 2.3 Palpitations
- 2.4 Biomarkers
 - 2.4.1 Inflammatory markers
 - 2.4.2 Uric acid

3. Aims of thesis

4. Study population and methods

- 4.1 The Tromsø Study
- 4.2 Tromsø 4 cohort
- 4.3 Data collection and ascertainment of endpoints
- 4.4 Statistical analyses

5. Results

- Paper 1: Palpitations are predictive of future atrial fibrillation
- Paper 2: Inflammatory biomarkers as risk factors for future atrial fibrillation
- Paper 3: Uric acid is associated with future atrial fibrillation

6. Discussion of methodology

- 6.1 Study design
- 6.2 Internal validity
- 6.3 External validity

7. Discussion of main results

- 7.1 Prevalence and incidence

7.2 Traditional risk factors:

Age, gender, hypertension, coronary heart disease, obesity, diabetes

7.3 Palpitations

7.4 Inflammation

7.5 Uric acid

7.6 Lone AF

7.7 Gender differences

8. Conclusions

9. Implications

References

Papers

Appendices

SUMMARY

Atrial fibrillation (AF) is a common cardiac arrhythmia, which increases morbidity and mortality and thereby imposes high health costs on society. The prevalence of AF has increased for several decades, and is expected to increase further, with the rising numbers of elderly people and survivors of heart diseases. Several risk factors for AF related to genetics and diseases have been established. Focus is now also set on novel risk factors related to symptoms, life style and inflammation. The identification of risk factors is important, as some of them could be modifiable.

The population-based Tromsø Study made it possible to follow survey participants from the fourth survey in 1994, who were free of AF at baseline, to study different risk factors for AF and the impact of these. We also wanted to investigate the frequency of AF in our population. All research questions were analysed with a gender perspective.

We were able to follow nearly 23 000 persons for a mean of 11 years, and found that 2.2% of women and 3.3% of men in this population were diagnosed with AF.

A main new finding was the importance of self-reported palpitations as a risk factor for AF. The association was stronger in men than in women. We also found different strength of associations in women and men for several other variables. Coronary heart disease and overweight were stronger risk factors in men. Hypertension was a stronger risk factor in women, and diabetes predicted AF in women only.

A limited number of inflammatory biomarkers were available for this study. We found that hs-CRP was associated with future AF in men, but not in women. Moreover, we found a significant increase in AF with increasing levels of white blood cells.

We also found that serum uric acid was a strong risk factor for AF, and the predictive ability was stronger for women than for men.

Low physical activity, vigorous exercise, smoking and use of alcohol were not associated with AF in this population.

The findings imply that adequate antihypertensive treatment is probably important to prevent AF, as is the prevention of coronary disease and diabetes. Patients with palpitations are prone to AF and should be investigated further. The possible clinical importance of the positive associations with inflammatory biomarkers and uric acid needs further investigation in other populations.

SAMMENDRAG

Atrieflimmer (AF) er en relativt vanlig arytmi, som øker sykkelighet og dødelighet, og dermed også samfunnets behandlingsbehov og helsekostnader. Prevalensen av AF har økt gjennom flere tiår, og er forventet å øke ytterligere, på grunn av økende antall eldre i befolkningen, og fordi flere lever lenger med hjertesykdom. Flere risikofaktorer for AF er kjent. Dette gjelder både genetiske disposisjoner, og ulike sykdomstilstander. Det fokuseres nå også på nyere risikofaktorer relatert til symptomer, livsstil og inflammasjon. Kartlegging av risikofaktorer er viktig, fordi noen av disse kan tenkes å være modifiserbare.

Den befolkningsbaserte Tromsøundersøkelsen har gjort det mulig å følge deltakerne fra den fjerde studien i 1994, for å se på ulike risikofaktorer for AF, og hvor stor betydning disse har. Vi ville også undersøke hyppigheten av AF i denne befolkningsgruppen, og om det er forskjeller mellom kjønnene.

Vi fulgte nærmere 23000 personer i gjennomsnittlig 11 år, og fant at 2,2 % av kvinnene og 3,3 % av mennene i vår studiepopulasjon fikk påvist AF. Et nytt hovedfunn i vår studie var betydningen av palpitasjoner. Dette vanlige symptomet som ble rapportert av 27 % av kvinnene og 18 % av mennene, doblet risikoen for AF hos menn og økte risikoen med 60 % hos kvinner. Vi fant også kjønnsforskjeller for flere andre risikofaktorer, der assosiasjonsstyrken var ulik hos menn og kvinner. Koronarsykdom og overvekt var sterkere risikofaktorer hos menn. Hypertensjon var en sterkere risikofaktor hos kvinner, og diabetes predikerte AF bare hos kvinner.

Et begrenset antall inflammatoriske biomarkører var tilgjengelige fra denne undersøkelsen. Vi fant at hs-CRP var assosiert med AF hos menn, men ikke hos kvinner. Det var også økende hyppighet av AF med økende nivå av hvite blodlegemer.

Vi fant videre at serum-urinsyre var en sterk risikofaktor for AF, spesielt for kvinner.

Vi fant ingen assosiasjon mellom lav fysisk aktivitet, hard/intensiv fysisk aktivitet, røyking eller alkohol i denne populasjonen.

Funnene tyder på at adekvat antihypertensiv behandling trolig er viktig for å forebygge AF, likeens vil forebygging av koronarsykdom og diabetes være viktig. Pasienter med palpitasjoner har risiko for å utvikle AF, og bør derfor følges opp. Betydningen av urinsyre og de inflammatoriske biomarkørene bør undersøkes videre i andre populasjoner.

LIST OF PAPERS

1 Nyrnes A, Mathiesen EB, Njølstad I, Wilsgaard T, Løchen ML.

Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: the Tromsø Study.

Eur J Prev Cardiol. 2013 Oct;20(5):729-36. doi: 10.1177/2047487312446562. Epub 2012 May 15.

2 Nyrnes A, Njølstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Skjelbakken T, Jørgensen L, Løchen ML.

Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromsø study.

Gend Med. 2012 Dec;9(6):536-547.e2. doi: 10.1016/j.genm.2012.09.001. Epub 2012 Oct 6

3 Nyrnes A, Toft I, Njølstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Løchen ML.

Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women--the Tromsø Study.

Europace. 2014 Mar;16(3):320-6. doi: 10.1093/europace/eut260. Epub 2013 Aug 30.

ABBREVIATIONS

ACE-I	Angiotensin-converting enzyme inhibitor
AF	Atrial fibrillation
BP	Blood pressure
BMI	Body mass index
CHD	Coronary heart disease
CI	Confidence interval
CRP	C-reactive protein
CVD	Cardiovascular disease
DBP	Diastolic blood pressure
ECG	Electrocardiogram
GFR	Glomerular filtration rate
HDL cholesterol	High density lipoprotein cholesterol
HR	Hazard ratio
hs-CRP	High-sensitivity C-reactive protein
MI	Myocardial infarction
OPG	Osteoprotegerin
SBP	Systolic blood pressure
SD	Standard deviation
SUA	Serum uric acid
WBC	White blood cells

1. INTRODUCTION/BACKGROUND: Why study atrial fibrillation?

Atrial fibrillation (AF) is the most common disturbance of heart rhythm. The condition confers an increased risk for morbidity and mortality. Despite this, AF has formerly often been regarded as a fairly trivial disorder, and the importance of treatment has been unrecognised. The reason for this neglect can assumedly be related to the lack of knowledge about pathophysiology, risk factors and consequences, as well as missing knowledge and possibilities for good treatment.

AF was described already in ancient Chinese medicine. In Europe, AF was described in the 12th century by Moses Maimonides, a Spanish/Jewish philosopher and physician. The English physician William Harvey described the fibrillation of auricles in animals in 1628. William Withering, another English physician, introduced the treatment with digitalis in 1785. A step further in the approach came with the invention of the stethoscope by René Laënnec in 1816. However, the real investigation and understanding of AF emerged when the electrocardiogram (ECG) was developed (Einthoven 1900) and with the further development of electrophysiology. The British cardiologist Thomas Lewis was the first to record AF with ECG in 1909. Now AF medicine has developed into a high-tech area, as new treatment possibilities have developed, especially with the ablation techniques.

This thesis is an epidemiological study of frequency and risk factors for AF in a general population. Therefore, the diagnosis and management of AF is beyond the scope of the study, and will not be addressed. The mechanisms of pathophysiology will also be addressed very briefly, but needs mentioning due to the link to risk factors.

1.1 What is AF?

AF is an irregular and often rapid heart rate, characterised by predominantly uncoordinated atrial activation with consequent deterioration of atrial function. The electrical signals are generated from multiple foci in the atria, typically the areas around the pulmonary veins, instead of following the normal coordinated pathway from the sino-atrial node. This results in a fibrillating atrial activity, which is inefficient and leads to inadequate emptying of the atria. The electrical impulses reaching the atrio-ventricular node will be conducted further to a various degree, and result in irregular contractions of the ventricles, out of coordination with the atrial contractions, and with variable cardiac output. The result is typically poor and irregular blood flow to the body, depending on the amount that has flowed from the atria to the ventricles with each beat.

The diagnosis of AF needs confirmation by an ECG. Distinct P-waves are lacking, and the QRS-complexes will appear “irregularly irregular”.

Figure 1. ECG



Electrocardiogram showing atrial fibrillation (upper lead). P waves are absent and replaced by irregular electrical activity. The ventricular rate is irregular and chaotic. Lower lead: normal. (Illustration: Wikipedia)

1.1.1 Classification

AF has traditionally been classified by its temporal pattern, clinical presentation and response to treatment, and divided in the following groups: (1)

- Paroxysmal: intermittent, self-terminating AF, i.e. spontaneous restoration to normal. Duration may be from less than one hour, up till maximum one week.
- Persistent AF: Duration of one week or more, not self-terminating, often with the need of medical or electrical cardioversion.
- Long-standing persistent AF: refers to persistent AF that has lasted for one year or more.
- Permanent AF: persistent and longstanding AF where restoration to normal rhythm no longer is possible.

A new classification system of AF, based on underlying mechanisms rather than just the symptoms or duration, was proposed by AFNET/EHRA consensus group in 2011. (1) A classification like this could help to better select therapies for specific AF patients.

In addition, the term “lone AF” has generally referred to patients with paroxysmal, persistent, or permanent AF who have no cardiopulmonary disease, hypertension included, and where other precipitating conditions are excluded. The term has primarily been applied to patients younger than 60-65 years of age. As this will only apply to a (small) minority of AF patients, studies on lone AF are scarce and have also rendered inconsistent findings. The risk factors for lone AF may differ from


those known to be associated with AF in general. It is possible that lone AF represents a somewhat different condition with other pathophysiological mechanisms.

AF is generally considered a progressive disease, with the tendency to become permanent over time, during which a combination of molecular and structural changes makes it difficult to restore and maintain sinus rhythm.

1.1.2 Pathogenesis/pathophysiology

The pathogenesis of AF is highly complex and is only partly understood. Current evidence indicates multifactorial causes. I will here only briefly mention some aspects of the morphological and electrophysiological alterations that may promote AF.

Figure 2. Mechanisms of AF



2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, JACC Dec 2, 2014

AF indicates atrial fibrillation; Ca⁺⁺, ionized calcium; and RAAS, renin-angiotensin-aldosterone system. Reproduced with permission from the publisher

AF is a result of “electric chaos” in the atria. This appears to require both an initiating event (trigger) and a permissive atrial substrate. Focal ectopic activity and multiple wavelets have been shown as such triggers. This causes *electrical remodelling*, which can be demonstrated within minutes after onset. The electrical remodelling alters ion channel function. The atrial refractory period is shortened and rate adaptation is lost. This may lead to re-entrant circuits. (2, 3)

Structural remodelling may precede the onset of AF, as in cases of present cardiac disease and atrial dilatation, or may be a result of persisting electric changes. The most frequent structural changes are atrial fibrosis and loss of atrial muscle mass. Fibroblasts can couple electrically to cardiomyocytes and promote reentry and/or ectopic activity. Inflammatory changes have been demonstrated in atrial biopsies, and inflammation appears to contribute to the structural changes in AF, as does oxidative stress. (2, 3)

Autonomic nervous system factors are also important in AF. *Autonomic neural remodelling* contributes to positive feedback loops that promote AF persistence and recurrence. (4) The clinical forms, and the evolution from paroxysmal to persistent to permanent AF, are considered to reflect the progressing electric and structural changes in the atria.

Risk factors associated with future AF may influence the substrate, and possibly also the triggers, for AF onset and persistence.

1.2 Clinical implications of AF

A 2012 consensus statement described AF as one of the major common and chronic disorders in modern cardiology, adding that mortality and morbidity associated with AF "remain unacceptably high". (1)

Symptoms of AF may vary, from lacking or negligible, to serious. Common symptoms include palpitations, fatigue, lightheadedness, dyspnea on exertion, and initiation or aggravation of angina, causing reduced quality of life and the need of health care.

The most serious complication of AF is arterial thromboembolism. Many factors have been shown to contribute to this. Due to altered and deteriorated contractility with insufficient emptying of the atria, blood stasis and atrial clot formation can occur. In addition, abnormal changes in blood constituents have been described, including haemostatic and platelet activation. Moreover, inflammation is likely to contribute. (5)

The most clinically evident thromboembolic event is ischemic stroke. AF increases the stroke risk up to five times. (6, 7) AF is present in 15-30% of patients with acute stroke and is associated with a 1.5- to 3.0-fold higher mortality compared to stroke patients in sinus rhythm. Strokes attributed to AF also tend to be more severe, resulting in greater disability, longer hospital stay, and lower rate of patient discharge to own home. (6, 8, 9)

Paroxysmal AF have been thought to imply the same stroke risk as persistent or permanent AF, as indicated in a Swedish study from 2010. (10) However, other trials have reported higher stroke risk in patients with permanent compared to paroxysmal AF. This was also concluded in two studies published lately, (11, 12) also in patients receiving anticoagulation.

Moreover, AF has been shown in a number of studies to be associated with impaired cognitive function, also in subjects without a history of stroke. (13-16)

AF is associated with a tripled risk for heart failure, and a doubling of the overall mortality risk. (17-19)

AF also seems to be a risk factor for incident myocardial infarction (MI). A recent US study found that subjects with AF had a 2-fold increased risk for MI, which remained significant after adjustment for known risk factors for coronary heart disease and the use of warfarin, and with a stronger association in women. (20)

AF patients need hospitalization twice as often as those without AF, when adjusted for comorbidities. (19, 21) Hence, hospitalizations attributable to AF represent a substantial and increasing economic challenge in many countries.


Due to the high prevalence of AF, this condition represents a large health burden with high costs for society. All indicators point to an increasing burden of AF in the 21st century. Estimates vary, due to different methodologies, but all investigators agree that an increase is indisputable, and that a 2.5 fold increase in prevalence is a cautious estimate. (22-24) Hence, it is important to investigate possible strategies to limit and preferably prevent the development of AF. The identification of risk factors serves the purpose of pinning down potentially modifiable factors, with the hope of reducing health problems.

1.3 Epidemiology of AF

1.3.1 Prevalence

The overall prevalence of AF has previously been estimated to 1-2% in the general population, and has been found to double with each decade from the age of 50 years to a prevalence of approximately 10% in those aged 80 years or more. (22, 25) The condition is uncommon, but not absent, in younger persons. Estimates of prevalence are highly dependent on the methods used for identification and ascertainment of AF. As many cases of AF are silent and/or paroxysmal, these are easily missed in studies. (See also chapter 6.2, paragraph re. information bias and misclassification.)

Figure 3. Prevalence of atrial fibrillation with age. The ATRIA Study



Data from Go AS, Hylek EM, Phillips K, et al. *JAMA* 2001; 285:2370. (ATRIA study)

Reproduced with permission from the publisher


The prevalence of AF is lower among black African/Caribbean and South Asian ethnic groups than in the white population. (26, 27) This is despite some common risk factors, e.g. hypertension and diabetes, being more prevalent among these groups. These consistent ethnic differences in prevalence and outcome are unlikely to be due to differential ascertainment. (27) White patients also have a higher risk of postoperative AF than black and other non-Caucasian patients. (28)

A review by Ball and co-workers 2013 presents pooled analyses of population data, suggesting that the overall prevalence in the adult population is more likely between 2.5% and 3.5%. (24)

1.3.2 Incidence

Studies of incidence of AF have yielded varying numbers, due to heterogeneity of the populations studied, and the prevalence and type of concomitant diseases, especially cardiovascular diseases. Incidence numbers from published data are therefore difficult to compare. All studies have demonstrated that AF incidence increases with age, and is higher in men than in women. Three of the most cited American population studies, published between 1994 and 2006, are compared in figure 4.

Figure 4. Incidence of AF per 1000 person-years stratified by age in the Framingham Heart Study, the Cardiovascular Health Study (CHS), and the Olmsted County Study.



Miyasaka Y et al. *Circulation* 2006;114:119-125

Reproduced with permission from the publisher

In Europe, incidence in the Rotterdam Study (published 2006) was similar to the data from North America. A recent, large study from Germany found higher incidences than previous studies, especially in the age groups above 70 years. (29)

Population studies performed in the 1980s and 1990s indicated an increasing incidence over time. However, newer data from US have shown stable incidence rates. This applies to the ARIC Study 1987-2004, (26) among Medicare beneficiaries 1993-2007 (30) and also recent data from Olmsted county 2000-2010. (31)

1.3.3 Increasing numbers

Population studies have consistently indicated increasing prevalence, and until lately also increasing incidence. (23, 24, 32, 33) The reason for this increase is partly due to ageing populations, surviving with more comorbidities predisposing for AF. In addition, the increasing focus on AF, as well as improved diagnostic tools, has led to the detection of a larger proportion of AF patients. The impact of risk factors may also have changed. As an example of such, obesity and diabetes, both of which are associated with AF, have increased in the population.

A recent report from the Framingham Heart Study presents 50-year trends in prevalence and incidence of AF. In the sex-stratified and age-adjusted analysis of more than 200 000 person-years, both prevalence and incidence showed a roughly four-times increase, somewhat lower for women. However, the incidence of AF by Framingham Heart Study ECGs did not change significantly over time, and the researchers conclude that the trends of increased prevalence and incidence of AF partly are due to enhanced detection. (34)

1.3.4 Gender differences

At all ages, the prevalence and incidence of AF is higher in men than in women, across all studies and in all age groups. (24) The reason for this gender difference remains unknown. In the older age groups (80+), more patients are female, due to the age composition in the population, with more women surviving to old age. Patients in the youngest age groups are predominantly men. Women tend to be on average 5 years older than men when they are first diagnosed with AF. (35, 36) This could in part be related to concomitant diseases; especially coronary heart disease (CHD) which is a strong risk factor for AF and which also has a later onset in women. Still, the gender differences in prevalence and incidence remain after adjustment for such comorbidities.

At time of AF presentation, men more often have CHD and more heart failure with reduced systolic function. Women have more hypertension, heart failure with preserved systolic function, valvular disease, and diabetes. (35-37)

Many studies have found that risk factors for AF are differently distributed in women and men, and also that the risk factors show various strength of association in the two genders. However, these differences are not consistent throughout the studies. This could be explained by differences in the populations studied, and that adjustment for confounders has been done differently.

2. RISK FACTORS

Risk factors are usually addressed under the heading “epidemiology”. However, as this thesis entirely focuses on risk factors, I have chosen to present these in a separate chapter.

A risk factor is a characteristic or exposure, associated with an increased risk of a condition or disease. Risk factors may be biomedical, behavioural, environmental, demographic or genetic. Risk factors are correlational, but not necessarily causal. They do not prove causation, but can be part of the causal chain. The identification of risk factors is important, as some of these may be modifiable. A modification of risk factors may help reduce health problems.

2.1 Genetic factors

The knowledge in this field is rapidly changing and increasing, and will therefore be mentioned very briefly here.

Genetic factors have been assumed to play a role in AF, as the condition can be observed to affect several members of certain families. A genetic disposition may particularly be of importance in cases of lone AF, which affects otherwise healthy individuals. (38-40) Over the past decade, genome-wide association studies (GWAS) have led to the identification of multiple gene variants that confer increased susceptibility to the arrhythmia. These genes encode ion channels, transcription factors, and signalling molecules. (41) The Tromsø Study has also contributed in the genetic analyses, in cooperation with Icelandic researchers who showed a 21% increased risk for AF in the presence of a certain gene variant. (42)

The heritability of AF is complex. For the majority of patients, a possible genetic susceptibility is probably a polygenic phenomenon, meaning that it is due to the combined effects of a number of genes, in addition to the effect of other risk factors.

2.2 Cardiovascular, life style related and other risk factors

2.2.1 Cardiovascular risk factors

The most studied risk factors for AF are those related to cardiovascular disease (CVD). These factors have been studied in large, and more selected, populations in many countries.

Hypertension has consistently been found to be one of most important risk factors. (18, 37, 43) Although the increase in risk is relatively modest (relative risk 1.2-1.5), (7) hypertension is considered the most significant population-attributable risk factor for AF, due to the high prevalence in the general population. Hypertension is associated with structural changes in the heart, related to left atrial enlargement and left ventricle hypertrophy. (44) The electrical remodelling occurs early in hypertensive heart disease. (45) This can lead to atrial and ventricular arrhythmias. The activation of the renin-angiotensin-aldosterone system is important in hypertension, and also in the development of atrial fibrosis which is correlated to AF. (46-48)

CHD, valvular disease and congestive heart failure (CHF) are well known risk factors for AF. (17, 24, 37, 43, 49)

In the Framingham Study, CHF imposed the greatest risk, with a 4.5-fold increase risk for AF in men and a 5.9-fold increased risk in women. (7) CHF may, among others, be the result of hypertension, valvular disease, CHD or even tachy-arrhythmias like AF, but is a risk factor for AF even when adjusted for these comorbidities.

Valve disease appears to be a stronger risk factor for AF in women. In the Framingham Study, the OR was 3.4 in women and 1.8 in men, in risk factor adjusted analysis. (37)

CHD is a stronger risk factor in men. In Framingham, the odds ratio for AF was 1.4 in men with previous myocardial infarction, while the association in women was not significant. (37) Other large population studies have not given information on sex-specific analyses. However, in most reports men are more likely to show ECG evidence of past myocardial infarction.

2.2.2 Life style related risk factors

Life style factors have shown an association in some studies, while others have failed to establish a correlation.

Smoking was shown to increase the risk for AF in the Rotterdam Study (50) and also in the ARIC Study, (51) while other large population studies (Cardiovascular Health Study, Renfrew/Paisley Study, Copenhagen City Heart Study, Danish Diet Cancer and Health Study) found no significant association.

Alcohol in light to moderate amounts appears to be associated with a lower risk of CVD and also with all-cause mortality. Heavier use, as well as abstention, is associated with a higher risk. The effects on AF are less clear, as studies have been diverging. Episodic high alcohol consumption as a trigger of arrhythmias, AF included, has been recognised since 1978 (52) and is termed the “holiday heart syndrome”. Several epidemiological studies have found that habitually high alcohol consumption is

associated with incident AF. (53-55) A meta-analysis 2011 concluded that the risk of developing AF is increased with increasing levels of alcohol intake, while the effect of light drinking remains uncertain. (56)

Coffee has been reported by some patients to trigger paroxysms of AF. However, larger studies have found no significant association. (57-59)

Poly-unsaturated fatty acids (PUFAs) have been hypothesized to have anti-inflammatory and anti-arrhythmic effects and to protect against AF. Studies in this field have yielded mixed and mostly disappointing results. A meta-analysis of seven cohort studies and 11 randomized controlled trials, published 2012, showed no significant reduction of incident AF with PUFA-exposure. (60) Several studies assessing PUFAs for the prevention of post-operative AF and post-ablation recurrence of AF have also showed no significant effect, as summarized in a meta-analysis 2013. (61)

Physical activity has been much focussed in later years, as long-time vigorous exercise (typically marathon and similar activities) has been shown in several studies, both clinical and meta-analyses, to increase the risk for AF. (62-65) Light to moderate physical activity has shown no increased risk, and could also have a protective effect, according to the same analyses. A favourable effect could partly be mediated via positive effects on cardiovascular risk factors.

2.2.3 Other life-style related and non-cardiac risk factors

Hyperthyroidism is a well-known risk factor for AF. Other conditions that have come into attention in recent years include obstructive sleep apnea, chronic kidney disease, chronic inflammatory disease, and surgery, especially cardiac.

Obesity has been investigated in a number of studies of various designs, and has consistently been found to increase the risk for incident AF. (66-69)

Diabetes has also shown an association in most studies. (37, 49, 70)

Obesity and diabetes frequently co-exist, along with hypertension, obstructive sleep apnea, CVD, chronic kidney diseases and inflammatory states, all of which are also correlated with AF.

2.3 Palpitations

Palpitations are a sensory symptom, an awareness of the beating of the heart, which may be felt as rapid, irregular or forceful and often is perceived as unpleasant.

The biological mechanism for this is not elucidated, which is also stated in the position paper from the European Heart Rhythm Association in 2011, Management of patients with palpitations: “Little is known about the events responsible for heartbeat sensation, the afferent sensory pathways that are involved, or the higher-order cognitive processing that filters, modulates, and amplifies these stimuli and brings some to conscious attention.” (71) Palpitations can be a benign sensation, or indicate a dangerous arrhythmia. Studies concerning the frequencies of significant arrhythmias in persons reporting palpitations have yielded highly varying results, depending on the population studied.

Two previous publications from the Tromsø Study have addressed the phenomenon of palpitations, but found a poor relationship between perceived palpitations and recorded arrhythmias, as assessed by 24-h ambulatory ECG in a population sample. (72, 73) The importance of self-reported palpitations on later occurrence of AF has not been documented until now.

2.4 Biomarkers in AF

A biomarker (biological marker) is a substance that can be objectively measured and used as an indicator of a biological state such as a disease or condition. In a wider definition, a biomarker can also be a biologic feature, characteristic or process. Biomarkers have been widely studied in medical research and in clinical medicine, and are increasingly used in the assessment of present and future disease. In AF research, a large number of biomarkers have been studied and have shown an association with AF, however conflicting. Whether an associated biomarker has a causal relationship to this condition, or is a confounder or merely a bystander, often remains a highly challenging problem. With further research, biomarkers associated with future AF can hopefully be used to improve clinical risk assessment. Moreover, they could also improve the understanding of the pathophysiology, and eventually point to new treatment possibilities.

2.4.1 Inflammatory markers

The correlation between inflammation and cardiovascular disease has been recognised through several decades. However, a causal relationship is still debated. The role of inflammation in AF pathogenesis was first reported in 1997, when histologic changes consistent with myocarditis in atrial tissue were demonstrated in patients with AF. (74) Inflammation has later been shown in several studies to be associated with AF, although results are inconsistent. However, the majority of studies

report elevated levels of inflammatory markers in AF compared with controls. To which extent the inflammation is causal is still being debated, but the inflammatory process seems to have importance both for the development and perpetuation of AF. (75) Studies have also indicated a correlation between inflammatory markers and the AF burden. (76)

Four inflammatory biomarkers were available for the analyses in this thesis: high-sensitivity CRP (hs-CRP), osteoprotegerin (OPG), white blood cells (WBC) and fibrinogen.

The most studied inflammatory biomarker is C-reactive protein (CRP), considered to reflect underlying disease processes associated with AF. Special attention has been paid to hs-CRP, as a marker of low-grade inflammation, which has proven to be a risk factor for cardiovascular disease in general, and also for AF in some studies. (76, 77)

OPG is a novel biomarker that has gained interest as a marker of CVD. OPG is associated with inflammation, vascular calcification, endothelial function and atherosclerosis. A recent study from Tromsø showed that high plasma OPG is a strong predictor of CVD and mortality, in high risk and general populations. (78) As far as we know, only one previous study has addressed a potential correlation between OPG and AF. This is a report from the Framingham Offspring Cohort published 2009, where OPG no longer was associated with AF after adjustment for MI and heart failure. (79)

The level of WBC as a marker of future AF in a general population has, to our knowledge, not been investigated previously.

Fibrinogen has been studied with conflicting results regarding the prediction of AF. Some population studies have found that fibrinogen predicted future AF, (77, 80, 81) while others did not find such a correlation. (79, 82, 83)

2.4.2 Uric acid

Uric acid (UA) is an “old” substance that has gained new attention. Apart from its ability to cause gout and stone formation, UA was for many years thought merely to be the metabolically inert waste product of purine metabolism. However, the last decades have provided increasing evidence that this substance is biologically active, and is involved in many biological functions.

UA is the breakdown product of purine catabolism. UA is excreted in the kidneys, but approximately 90% of filtered UA is reabsorbed. The reason for this reabsorption is not fully understood, as high

levels of UA have been shown to be unfavourable in many aspects. However, it is reasonable to assume that UA has also had beneficial effects through evolution and physiology.

Increased serum UA levels have been found to be associated with hypertension, inflammation, CVD, obesity, endothelial dysfunction, renal disease and diabetes. All these conditions are also associated with AF. UA has especially been studied as a marker of CVD and a measure of CVD risk factor load. Increased UA levels were independently and significantly associated with risk of cardiovascular mortality in the NHANES study. (84) In a Finnish population-based prospective cohort study, UA levels were a strong predictor of cardiovascular disease mortality in healthy middle-aged men, independent of variables commonly associated with gout or the metabolic syndrome. (85) In a large Austrian cohort of elderly women, UA was an independent predictor for all major forms of death from CVD, CHF and stroke. (86) A recent publication from the Tromsø Study also confirmed that UA is a risk factor for ischemic stroke and all-cause mortality in a general population. (87)

UA has shown to have strong antioxidant activity, and also seems to have protective effects against neurodegenerative diseases like Parkinson's disease and multiple sclerosis, (88-90) and also motor neuron disease (ALS). (91) Some of these studies have shown a gender difference, as the favourable effect was seen predominantly in men. The relation between uric acid and cognitive decline, in which both vascular mechanisms and oxidative stress are thought to play a role, has been studied with somewhat conflicting results. In a publication from the Rotterdam Study 2009, higher UA levels were associated with a decreased risk of dementia, after adjustment for cardiovascular risk factors. (92) By contrast, hyperuricaemia was related to white matter atrophy and worse cognition in another publication from the Rotterdam Study 2013. (93) However, some new, large, population based cohort studies have shown that patients with gout have a lower risk of developing dementia, supporting the purported potential neuroprotective role of uric acid. (94, 95)

UA levels in men are higher than in women throughout life, although rising after menopause. Women have a lower risk for gout than men do at comparable uric acid levels, according to 52-year follow-up data from the Framingham Heart Study. (96) However, several studies have found that the effect of UA seems more detrimental in women. This has been shown for cardiovascular risk, (97-99) mortality (84) and diabetes. (98, 100) However, most studies did not perform sex-specific analyses.

An association between UA and AF has been indicated in a few studies. (101-103) This association could partly be mediated through CVD and hypertension, but multivariable analyses have indicated that an independent effect is also possible.

3. AIMS OF THESIS

The overall aim was to identify and investigate occurrence and risk factors for future AF in a longitudinal study of a large general population. All analyses were performed in sex-specific models.

The specific aims were the following:

1. to study prevalence, incidence and traditional risk factors for AF, and especially to investigate the effect of palpitations in prediction of incident AF
2. to study the association between inflammatory biomarkers hs-CRP, OPG, WBC and fibrinogen and future AF
3. to study the association between uric acid and future AF

4. STUDY POPULATION AND METHODS

4.1 The Tromsø Study

The Tromsø Study is a single centre longitudinal study of the population in the municipality of Tromsø, Norway. The study was initiated in 1974, with the main focus on determinants and distribution of cardiovascular diseases, and how to prevent these. Cardiovascular mortality was high in Norway at that time, and even higher in Northern Norway than in the nation as a whole.

The Tromsø Study is also a longitudinal study, as the surveys have been repeated at regular intervals. In addition, the study has gradually expanded to include a variety of diseases and health aspects. The design ensures the inclusion of total birth cohorts and random samples, and involves a large proportion of the adult population. High-risk individuals have been invited to sub-studies.

The sixth Tromsø survey was performed in 2007-08. At this point, a total of 40 051 persons had participated in at least one of the six surveys, while 15 157 had participated on three or more occasions, and 1235 persons had participated in all six studies. The seventh Tromsø survey is scheduled to 2015-16, with the invitation of 33 000 persons. The Regional Committee for Medical and Health Research Ethics, the Data Inspectorate and the Norwegian Directorate of Health have approved the surveys.

A letter enclosing a questionnaire, which they are asked to answer and bring to the examination site, invites all participants in the Tromsø Study. Here, the participants are handed a second questionnaire, where they are asked to give supplementary information. The two questionnaires have expanded over the years, and now contain information about a wide range of diseases and symptoms, medication, lifestyle aspects including dietary habits, smoking and physical activity, socio-economic status and ethnicity.

The physical examination consisted originally of the measurements of blood pressure, height and weight, and a blood sample for the analysis of haemoglobin and blood lipids. In later surveys, the physical examination has gradually been extended, as have the blood tests (104)(+ see appendix: questionnaires)

Blood samples for later analyses of novel biomarkers have been stored at each survey. Examples of such biomarkers that have been measured in stored samples include hs-CRP and OPG from the second visit of the fourth survey of the Tromsø Study (Tromsø 4).

4.2 Tromsø 4 cohort


The three papers in this thesis are all based on data from Tromsø 4 in 1994-95.

An overview of the study population is given in the flowchart (figure 5).

In Tromsø 4, all inhabitants 25 years and older (born 1897-1969) were invited. A total of 27 158 persons, 77 % of the eligible population, participated in the first visit of the survey. This group constitutes the study population in paper 1. After exclusions of persons who did not consent to research, those who had moved from the region, persons with known AF at baseline or insufficient data regarding AF, and persons with missing information on palpitations and diabetes, 22 185 persons were followed-up for eleven years.

A pre-defined selection of the participants was invited to a more extensive examination in a second visit, usually within 1-3 months after the first visit. The eligible subjects were identified before attending the first visit. The second visit comprised more specialized physical and biochemical testing. Eligible for the second visit were all men aged 55-74 years (born 1920-39) and all women aged 50-74 years (born 1920-44), as well as 5-8 % random samples of the other age groups (25-54 years and 75-85 years). Of those invited to the second visit, 98 % attended (76 % of the 10 542 originally eligible subjects).

Figure 5. Flowchart, the Tromsø Study, 1994-2007



A total of 7965 persons attended the second visit. This group constitutes the basis for the study population in paper 2 and 3. Of the second visit attendees, 1055 were mainly screened for osteoporosis. This group was not part of the pre-defined second visit population, but was invited in a special project. The group consisted of younger women with a mean age of 49.9 years. Due to the highly selected age, and one gender only, we decided to exclude this group from our analyses. Forty-nine persons had withdrawn their consent to research and were consequently excluded.

In my data set, the selection variable 'date for examination in visit 2' provided 6834 subjects available for further analyses. After exclusions of persons who had moved from the region, persons with known AF at baseline or insufficient data regarding AF, and persons with missing data or high levels of hs-CRP (>10 mg/L), 6315 subjects were followed-up for eleven years in the study of inflammation (paper 2). In the study of uric acid, we did the same exclusions of persons who had moved from the region and persons with known AF at baseline or insufficient data regarding AF, as well as persons with missing uric acid measurements. This provided 6308 subjects with equally long follow-up in the study of uric acid (paper 3).

The populations in visit 1 and 2 thus differ in age, with a mean of 46 and 60 years respectively. The differences in other variables (e.g. blood pressure, BMI, blood lipids, diabetes, and antihypertensive treatment) can mostly be explained by the age difference.

Table 1. Baseline characteristics of participants in Tromsø 4, visit 1 and 2

	Women		Men	
	Visit 1	Visit 2	Visit 1	Visit 2
Age, years	45.8 (14.8)	60.5 (10.3)	46.2 (14.1)	59.5 (10.0)
Systolic blood pressure, mmHg	131.0 (21.6)	144.7 (24.3)	137.2 (17.0)	144.6 (20.3)
Diastolic blood pressure, mmHg	75.8 (12.4)	81.7 (13.4)	79.8 (11.6)	84.8 (12.1)
Heart rate, beats/min	73.0 (12.2)	73.9 (12.5)	68.8 (12.5)	69.8 (13.0)
Height, cm	163.9 (6.6)	161.5 (6.3)	177.2 (7.0)	175.2 (6.8)
Body mass index, kg/m ²	24.7 (4.1)	25.9 (4.4)	25.6 (3.3)	26.0 (3.3)
Total cholesterol, mmol/L	5.99 (1.37)	6.93 (1.34)	6.04 (1.21)	6.57 (1.20)
HDL-cholesterol, mmol/L	1.65 (0.41)	1.68 (0.43)	1.35 (0.35)	1.39 (0.39)
Alcohol, glass/14 d	3.3 (4.2)	2.5 (3.6)	6.6 (7.6)	5.5 (7.3)
Tee-totaller (%)	14.6	26.1	8.2	12.9
Smoking (%)	36.3	31.0	36.5	34.7
Physical activity (%)	45.6	28.2	60.7	47.1
Hypertension (%)	28.4	56.7	40.4	60.6
Anti-hypertensive treatment (%)	5.4	13.1	5.7	12.8
Coronary heart disease (%)	3.4	8.3	6.2	15.0
Diabetes (%)	1.8	3.9	2.1	4.4

4.3 Data collection and ascertainment of endpoints

Baseline characteristics were collected from the questionnaires, the physical examination and the blood analyses.

From the questionnaires, we selected information about self-perceived arrhythmia ('Have you noticed sudden changes in your heart rate or heart rhythm in the past year?'), and self-reported information on diabetes, angina, myocardial infarction, physical activity, smoking habits, coffee, alcohol and use of antihypertensive treatment.

Height, weight, blood pressure and heart rate were measured at the examination.

Blood tests from the first visit provided full haematological indices and blood lipids (total cholesterol, HDL-cholesterol and triglycerides).

Blood tests from the second visit also included hormones and a number of other substances, among which some inflammatory biomarkers and uric acid have been of special interest for this thesis.

The second visit questionnaire also provided information on anti-diabetic medication. This was incorporated in the definition of diabetes for the analyses in paper 3. ECGs were collected for a subgroup, but these were not available for our analyses.

All cases of AF have been verified in hospital records and validated by a physician.

The procedure for identification, definition and ascertainment of atrial fibrillation is described in detail in the papers. We searched for information on AF in the hospital records of all patients with a diagnostic code (International Classification of Diseases) of AF or other relevant arrhythmia.

Moreover, we performed systematic searches among subjects without an AF diagnosis, but who could be assumed to have an increased risk for AF. These were persons with other cardiovascular and cerebrovascular conditions, as well as 'instantaneous unexplained death' and 'death by unknown cause'.

4.4 Statistical analyses

All analyses were performed using SPSS for Windows. Version 15.0 was used for the analyses in paper 1, while the analyses for papers 2 and 3 were performed using version 19.0. Baseline characteristics are presented as means (standard deviation) or numbers (percent). Differences between groups were assessed by t-tests and χ^2 tests. Linear trends across quartiles of measured biomarkers were tested using linear regression models for continuous variables and logistic regression for binary variables. Age-adjusted and multivariable Cox proportional hazards regression

models were used to estimate hazard ratios (HRs) for AF with 95 % confidence intervals. The analyses were conducted separately for women, men and the total study population. Cross-product terms between sex and biomarker variables were added to the models to assess interaction. The proportional hazard assumption was assessed by visual inspection of log minus log plots of the survival curves. A two-sided p-value <0.05 was considered statistically significant.

5. RESULTS

Paper 1: Palpitations are predictive of future atrial fibrillation

This is a study of the total Tromsø 4 cohort, where we analysed 22 815 persons who were followed-up for eleven years. In this large, general population with a mean age of 46 years at baseline, 3.0% of women and 4.2% of men developed AF during follow-up.

We found that hypertension was a significant risk factor for AF. Raised blood pressure at baseline (above 140/90 mmHg) almost doubled the risk of AF in women (HR 1.98, 95% CI 1.46-2.69) and increased the risk by 40% (HR 1.40, CI 1.13-1.74) in men.

We found that self-reported diabetes was a significant risk factor for AF in women.

We could confirm that CHD is a strong risk factor, especially for men. We also found a clear gender difference in the impact of overweight, which was a stronger risk factor for men.

However, our main finding in this study was the importance of self-reported palpitations. Palpitations reported at baseline increased the risk of AF in women by 62% (HR 1.62, CI 1.29-2.02) and in men by 91% (HR 1.91, CI 1.54-2.35).

A low percentage was found to have lone AF, as this applied to only 4.4% of the female and 7.2% of the male AF patients. In our study population, 67% of lone AF patients were men. We found a significant relation between BMI and lone AF in men. We also found that height was a risk factor for lone AF in men. Women with lone AF seemed to be taller and leaner than AF women in general, but due to a low number in this group (n=16), these differences were not significant.

Paper 2: Inflammatory biomarkers as risk factors for future atrial fibrillation

In Tromsø 4, a full blood cell count (including subgroups of white blood cells, WBC) was collected of all participants. In visit 2, new blood samples were collected for the analysis of fibrinogen, high-sensitivity C-reactive protein (hs-CRP) and osteoprotegerin (OPG). The participants of visit 2, where 6315 subjects remained after exclusions, therefore constitute the study population in this paper.

We excluded persons with high values of hs-CRP, as we wanted to focus on low-grade inflammation. AF cases diagnosed during the follow-up period (n=566) were identified as described earlier.

In the multivariable analysis, adjusted for traditional cardiovascular risk factors and other inflammatory biomarkers, we found that hs-CRP was associated with future AF in men (HR 1.14 for a 1 SD increase; 95% CI, 1.02–1.28), but not in women.

CRP is considered to reflect the burden of CVD, which is a known risk factor for AF. We therefore also performed analyses where we excluded patients with prevalent myocardial infarction (MI) at baseline. This did not change the results; neither did adjustment for ascertained MI during follow-up. Thus, the association between hs-CRP and future AF does not seem to be mediated by CVD in this study population.

We found a significant increase in AF across quartiles of WBCs in men ($p=0.007$) and in the total study population ($p= 0.004$). Subgroups of WBCs showed no significant associations with AF.

OPG is a novel biomarker which is associated with inflammation, vascular calcification, endothelial function, and atherosclerosis, and which has shown to be a marker of CVD.

OPG was associated with incident AF in a model adjusted for age and sex, and in an age-adjusted model for women. The significance was lost with further adjustment for CHD and other confounders. However, OPG was associated with AF in patients free of CHD at baseline, in multivariable analysis in the total study population.

Fibrinogen showed no significant association with AF.

Paper 3: Uric acid is associated with future atrial fibrillation

Uric acid (UA) has been shown to be associated with cardiovascular disease in population studies, but its relation to AF is largely unknown.

In Tromsø 4, UA was measured in visit 2. We were therefore able to study 6308 participants who were followed-up for eleven years. During this observation period, 572 persons were diagnosed with AF. When adjusted for cardiovascular risk factors and concomitant diseases, UA was associated with AF in both sexes, with higher estimates in women (though the difference between women and men did not reach statistical significance). Hazard ratio (HR) per 1 SD increase in SUA ($91 \mu\text{mol/L}$) was 1.40 (95 % confidence intervals [CI], 1.14-1.72) in women, and 1.17 (95 % CI, 1.02-1.36) in men. The upper quartile of SUA conferred a 76 % increased risk for AF in women and 49 % in men as compared to the lowest quartile.

SUA also exerts its effects through raised blood pressure, and inflammation, both of which are important risk factors for AF. We therefore adjusted for these risk factors in the analyses, as well as CVD and other risk factors for CVD. This did not change the estimates.

6. DISCUSSION OF METHODOLOGY

6.1 Study design

A cross-sectional study (survey) is a study of a defined population at a defined point of time. This is a useful design to study the prevalence of a disease, condition or risk factor. It is also useful for hypothesis generation, but not for hypothesis testing. Repeated cross-sectional studies can detect changes in risk factors and disease frequencies in populations over time.

The Tromsø Study is a prospective follow-up study of the general population in the municipality of Tromsø. It is also a longitudinal study, as the surveys have been repeated at regular intervals. Thus, the Tromsø Study combines the cross-sectional and the cohort study designs.

All risk factors or exposures are collected at baseline, when all individuals are “healthy”, i.e. free of the condition we want to study. “Sick” or affected individuals are excluded from follow-up. The cohort is followed-up for a defined period of time, in this case eleven years, to see which individuals develop the condition or endpoint, in this case AF, and to assess possible risk factors for the condition.

6.2 Internal validity

This term refers to whether the results of a study are representative, true or valid for the population studied. Traditionally, two main problems need to be addressed here: bias and confounding.

Bias is a systematic deviation from the truth that distorts the results of research. This can occur in any process in any stage of a study, and produces a systematic error in the result.

Thus, bias can weaken a true association, or can produce a false association. Many forms of bias have been identified, but are often grouped into two main categories; selection bias and information bias. A total elimination of bias is not likely to achieve, as this would require a total degree of control. But through a thorough design and a careful conduct of study and analyses, bias can be reduced to a minimum, and the study can reach internal validity.

Selection bias will occur e.g. if the persons we want to study are not allocated in a standardized random way, and the groups we want to compare are actually different from the start. The association between exposure and outcome among those selected for analysis, for example the actual attendees of a population-based survey, may differ from the association among those who originally were invited. This kind of bias can be a problem in a population survey if the participation rate is low, and the individuals studied may not be representative of the entire population. Selection

bias can also occur if many participants are lost to follow-up. The design of the Tromsø Study, with the invitation of total birth cohorts and random samples, ensures a representative study population. High-risk individuals have been invited to sub-studies. The high attendance rates also help minimise selection bias, but we cannot exclude that the so-called healthy participant bias may have diluted the true associations between risk factors and outcome. The Regional Committee for Medical and Health Research Ethics does not permit analyses of non-attendees. However, we know from other studies that non-attendees may differ from those who attend a survey, in demographic characteristics and in prevalence of risk factors or diseases. (105, 106) In another Norwegian population-based study (the HUNT Study), the prevalence of common chronic diseases among non-participants was higher than in participants, and it is likely that the same is true for the Tromsø Study. (107)

Socio-economic status and education affect health awareness, life style and risk of disease. Non-attendees may be younger and healthier than the average participant (e.g. absent due to studies or lack of interest), or they may be older and sicker and therefore unable to attend. Non-attendees may also represent groups with lower health awareness and lower self-care abilities, and who tend to take less responsibility for own health.

Information bias and misclassification may occur during data collection, if the means for obtaining information about the subjects are inadequate. The main source of error is misclassification of exposure and/or outcome status. Misclassification of AF is an important possible source of bias in our study. Several steps were taken to ensure accurate classification of AF. Identification of possible cases was done through linkage to the University Hospital of North Norway (the only hospital in the area) and to the national Causes of Death Registry. In addition to the search for information on AF in the hospital records of all patients with a diagnostic code of AF or other relevant arrhythmia, we also performed systematic searches among patients with a diagnosis of CHD, stroke, or sudden or unexplained death. This led to the detection of many AF cases which would have been missed otherwise. Unfortunately, we did not register systematically the number of AF cases detected this way, but based on a similar search (related to the Tromsø-Iceland co-operative gene study) a rough estimate would be 100-120 cases, of the 822 cases in total, found in the study population in paper 1. However, we may still have missed a number of persons in our community with undiagnosed AF. Many AF patients are unaware of their arrhythmia and 5-40% of patients have been found to be asymptomatic. This is particularly common in older patients. (108) Many have the paroxysmal form which can be difficult to document on an ECG. Some AF patients may be taken care of by their family physician and have not been hospitalised with their AF.

It is difficult to give any assumption of the number of misclassifications due to non-detection. A British study from 1997 found that one third of AF patients were only seen by their general practitioner, and had not been hospitalised. (109) We have no such data from Norway. The referral pattern may differ, and may also have changed over time. Thus, the numbers cannot be inferred directly. It is also difficult to make assumptions about whether the AF group not seen in hospital is different from those who are referred. It could be speculated that those with symptomatic AF or with significant comorbidity would be referred, and that the non-referrals represent the healthier or asymptomatic group. On the other hand, younger people, i.e. those with presumed lone AF, might also be referred, as AF is an “abnormal” condition in the actual age group. The older people in whom the AF frequency is highest could be “spared” hospitalisation due to perceived lack of treatment consequences. It is also likely that the older patients, in whom AF symptoms more frequently are atypical or missing, will remain undiagnosed to a larger degree. This is likely to have caused an underestimation in our frequency analyses. If the old and asymptomatic, but co-morbid individuals are not detected, this could weaken the associations between the risk factors and AF.

All possible cases identified with a diagnosis of AF were validated by an endpoint committee, blinded for other information collected in the Tromsø Study. Only cases with information on documented AF in ECGs were classified as AF.

A possible misclassification problem should be mentioned regarding the biochemical analyses. Two of our predictor variables in the study of inflammation, hs-CRP and OPG, were analysed in frozen serum. The serum aliquots were stored for 12 years at -70°C and analysed without any freezing-thawing cycles before measurements. However, others have reported long-term stability of OPG when stored at -70°C . (110, 111) A study of CRP found that CRP values increased significantly, but slightly, after long-term frozen storage (112)

A *confounder* is a factor which is associated both with the exposure and the outcome variable, and which accounts for some or all of the observed relationship between the two. Confounding can thereby lead to under- or overestimation of an association. It may also change the direction of the effect, and it may obscure a true causal relationship. Examples of typical confounders are age and gender. As opposed to bias, confounding can be accounted for in statistical analyses. This can be done by stratification, e.g. by performing age- and sex specific analyses. Age adjusting is also a common method. Multiple regression analyses are frequently used to assess the effect of confounders. In our analyses, we have adjusted for known confounders such as traditional and more

novel cardiovascular risk factors. However, we obviously cannot fully exclude a confounding caused by unknown factors, for which we were unable to adjust.

6.3 External validity

This term refers to whether the results of a study are generalizable to other populations.

The design and the high attendance rates of the Tromsø Study have over years yielded results of high external validity and generalizability. The enrolment is based on the official population registry, thus ensuring that invitations are sent to the general population. The overall attendance rates have been high, 77-85% (with the exception of the sixth survey in 2007-08 when 66% of invited subjects attended). The vast majority of the participants have been of white, north-European ancestry, with few immigrants from other parts of the world, and the population of the Tromsø Study can therefore be assumed to be similar to other Caucasian populations, with similar prevalence of CVD and possibly also AF, and similar risk factors. There is only one hospital in this area, simplifying the identification of endpoints and ensuring that endpoints are reliable as far as possible. All inhabitants of Norway have a unique personal 11-digit identification number.

7. DISCUSSION OF MAIN RESULTS

7.1 Prevalence and incidence

Estimates of the total AF burden in our society are rough, and have been based on frequency analyses from other population studies (Framingham, Rotterdam, Copenhagen). These suggested a prevalence of approximately 1% in the total population. This may in reality be underestimated. A recent review presenting pooled analyses of population data suggest the prevalence more likely to be 2.5-3.5%. (24)

The frequency of AF has not been a main topic for the papers in this thesis. However, when the project was originally planned, we found it interesting to look into these numbers, as the prevalence of AF in a large, general Norwegian population had not been studied previously. I will therefore discuss briefly some of our findings.

Prevalence, total T4 population:

The cumulative prevalence of AF in the total cohort with a mean age of 46 years at baseline was 3.0 % in women and 4.2 % in men, for the total observation period.

The point prevalence at end of follow-up (December 31, 2007) was 2.2 % in women and 3.3 % in men (mean age 57 years).

Table 2. Point prevalence in age groups at end of follow-up

	Women			Men		
	Total cohort	Atrial fibrillation		Total cohort	Atrial fibrillation	
Age group	N	n	%	N	n	%
< 50	6272	17	0.3	5505	46	0.8
50-59	1569	43	2.7	1562	84	5.4
60-69	979	76	7.8	815	92	11.3
70-79	426	64	15.0	261	51	19.5
>80	37	2	5.4	7	0	0
total	9283	202	2.2	8150	273	3.3

This supports the overall pooled prevalence estimated by Ball and co-workers (24) in their review paper 2013 (men 0.033, women 0.024).

A direct comparison with the results found in other population studies is difficult, due to the age groups examined and the time of the study, as the prevalence has been reported to increase over time.

A cohort study of 75 year old inhabitants in two municipalities in southern Norway found a 10% prevalence of AF. (113) The table above shows a seemingly higher AF prevalence in our study population. However, this can partly be explained by the fact that the age groups here refer to the age at baseline, and the persons who developed AF were observed for a mean of 7.1 years before reaching their endpoint.

Incidence

The incidence rate for the total cohort (46 years at baseline) was 2.7 in women and 3.9 in men, per 1000 person-years. The incidence rate for the visit-2 population (60 years at baseline) was 7.2-7.3 in women and 9.5-9.6 in men. The populations in paper 2 and 3 are slightly different, due to exclusions. Hence, the incidence rates are also slightly different.

Our rates are apparently higher than what has previously been found in some other population studies. The Rotterdam Study, which analysed men aged 55-59 years, followed-up 1990 -99, found an incidence of 2.6. (33) There were no women in this age group of the study. In age group 60-64 years, the incidence was 4.9 for men and 2.1 for women.

In the Olmstead analyses from 2000, the age- and sex-adjusted incidence of AF per 1000 person-years was 3.7 (95% CI, 3.4 - 4.0). (23) This is a population with a high rate of North-European ancestry, which could therefore be presumed to be genetically similar to our population in Tromsø. Higher rates in the Tromsø Study could be attributed to a high level of detection. There is also a possibility that the incidence in our study population is higher, for genetic or other reasons, however, this remains speculative.

In the Reykjavik Study, for the observation period 1994-96, the incidence in age group 55-64 was 1.5 for women and 4.1 for men. (114)

In the Framingham Study, the incidence in the age group 55-64 years (which was the youngest) was 3.1 in men and 1.9 in women. (18, 37) Yet, these numbers date from an earlier study period (published 1994) and the incidence was found to increase in the proceeding years. However, it is likely that this increase partly can be explained by better detection methods. (34)

7.2 Traditional risk factors

In our study, we wanted to compare the risk factors for AF identified in other populations with the Tromsø Study participants (paper 1). Could we confirm the “traditional” risk factors? Would the associations be similar? Are there gender differences?

7.2.1 Age and gender

AF has been found to double in prevalence and incidence with each decade of age. (7) This is also confirmed in our study population. Ageing is accompanied by many changes in cardiac structure and function, as well as comorbidities known to predispose for AF. However, the increase in AF with age is seen also when adjusting for these conditions.

The reason for a male preponderance of AF risk is still unexplained. Most studies have found an approximately 1.5-fold higher risk among men, as was also confirmed in our analyses.

7.2.2 Hypertension

We could confirm that hypertension is a significant risk factor for AF. Raised blood pressure at baseline almost doubled the risk of AF in women and increased the risk by 40% in men. Other population studies have found a fairly similar risk in men and women. (7, 49) It is interesting to notice that a larger percentage of those who developed AF in our study, reported taking anti-hypertensive medication at baseline, but had in fact higher blood pressure than the non-treated. Therefore, hypertension that was not adequately treated could have contributed to the development of AF. In the 1980s and 1990s, the threshold for starting anti-hypertensive treatment was considerably higher than today, especially in older individuals, and target blood pressure was not much debated.

The increase in AF risk is relatively modest. The Framingham Heart Study reported an odds ratio of 1.5 in men and 1.4 in women. (37) The Manitoba Study found a relative risk of 2.3, (17) and the Malmö Diet and Cancer Study reported a hazard ratio of 1.8-1.7. (49) However, hypertension is the most prevalent independent and potentially modifiable risk factor for AF, (7) and up to 70% of patients with atrial fibrillation have a history of hypertension. (115) In our study, 80% of women and 70% of men who developed AF were hypertensive at baseline.

7.2.3 Coronary and other heart disease

Our study found that CHD is a strong risk factor, especially for men. This is in accordance with findings from the Framingham Study. (7) Moreover, valvular disease is a more frequent risk factor in

women, as also stated from Framingham. (37) We found that a higher percentage of women had valvular disease at the time of AF diagnosis (14.7% vs.12.8%). This difference was significant.

7.2.4 Other CHD risk factors

We found an inverse relation between total cholesterol and future AF. This has also been reported from the Cardiovascular Health Study in USA, (43) from Japan (116) and the ARIC study, USA. (117) The mechanisms for this are unknown. High blood lipids (total cholesterol and LDL cholesterol) are established risk factors for CHD, and statins are well documented in secondary prevention of CVD. Short term trials have indicated reduced odds for developing AF, however, there was significant heterogeneity between the trials. In longer and larger trials of statin versus control, no significant reduction in AF was found in a large meta-analysis published 2011. (118) Thus, trials have shown conflicting results or no effect on the prevention of AF. This could be in accordance with our and others' findings that cholesterol and future AF are inversely related. However, statins are shown to have other effects than lipid lowering, e.g. endothelium stabilizing and anti-inflammatory effects, which could act preventive.

7.2.5 Obesity

We could confirm that obesity (BMI) is a risk factor for AF. (Paper 1) This has been shown in many studies previously. (66, 67, 119) We found a clear gender difference in the impact of overweight, which was a stronger risk factor in men. This trend has been indicated in a few other studies. The Danish Diet, Cancer, and Health Study found a slightly higher risk in men than in women by increasing BMI. (67) A report from Framingham also found higher risk in men, but the significance was lost after adjustment for left atrial diameter. (66) Most studies of obesity as a risk factor for AF have not performed sex-specific analyses.

However, obesity has been reported to be a stronger risk factor in men, for incident AF related to acute myocardial infarction (120) and for AF after coronary artery bypass graft surgery. (121)

A recent report from Tromsø showed that men with overweight (BMI 25 kg/m² or more) were more prone to AF recurrence after ablation therapy (Espnes H. Atrial fibrillation ablation, Student assignment, UiT The Arctic University of Norway, Faculty of Health Sciences 2015).

Obesity can promote the development of AF through several ways. Obesity is associated with ischemic heart disease, higher blood pressure, insulin resistance and diabetes, increased inflammatory markers, and higher levels of uric acid. All of these have been found to increase the risk

for incident AF, also when adjusted for co-factors. It can be assumed that these obesity-related factors cause structural changes in atrial tissue.

A possible or probable link between obesity and AF could go via inflammation. Adipose tissue, which once was thought to be inert, has been proven to be highly metabolically active. Among other substances, adipocytes produce a number of inflammatory cytokines, which may contribute in generating a systemic inflammatory status. The topic of inflammation will be discussed later.

Visceral and pericardial fat has been much studied in recent years, and is known to imply a greater risk of metabolic and cardiovascular disorders than subcutaneous fat deposits. The Framingham Heart Study reported that pericardial fat volume predicts AF, independently of other measures of adiposity, including BMI. (122)

Obesity is linked to left atrial size, which is an independent predictor of AF onset. (66, 119, 123, 124)

Obesity is also associated with thickening of the myocardium and ventricular diastolic dysfunction. (125, 126) Both of these are known risk factors for AF.

A large Danish study published 2013 showed that obesity is also a risk factor for AF in young fertile women. This group with a mean age of 30 years was essentially healthy and therefore had a low risk for incident AF. Still, the probability of AF was significantly greater for obese and very obese. (127)

An interesting study from Australia 2013 showed that weight loss decreased AF burden and severity. The control group received general lifestyle advice. During the 15 months of follow-up, a significant reduction in interventricular thickness and left atrial area was also documented in the weight reduction group. This is probably the first study to show beneficial effects on AF of risk factor management. (128)

7.2.6 Diabetes

We found that diabetes was a significant risk factor for AF in women. This is similar to a large American study which compared 17 000 diabetic patients with an equally large, age- and gender-matched group of non-diabetics in an observational cohort design. After controlling for other risk factors, diabetes was a highly significant risk factor for AF in women, but not in men. (70) A higher risk for AF in women was also shown from the Framingham study. (7) However, several studies have found a significant association between diabetes and AF, but have not performed sex-specific analyses. A meta-analysis of cohort and case-control studies, published 2011, found after adjustment for publication bias that patients with diabetes had a 34% greater risk of AF. Studies that had adjusted for multiple risk factors reported a smaller effect estimate compared to age-adjusted

studies. (129) The authors comment that the true risk between diabetes and subsequent AF therefore may be closer to 25%. A gender difference is not addressed.

Diabetes and AF share a number of common risk factors. These include obesity, hypertension, inflammation, obstructive sleep apnea and renal function deterioration. In addition, both conditions are associated with increased left atrial size, micro- and macrovascular changes, atherosclerosis and congestive heart failure. Diabetes and AF therefore are closely related.

The physiologic mechanisms linking diabetes and AF are not well elucidated. Diabetes is associated with left atrial enlargement and left ventricular hypertrophy, most prominent in women, (130) and with diastolic dysfunction. (131) Diabetes is associated with elevated CRP and other inflammatory markers, (76) which may promote myocardial fibrosis and diastolic dysfunction. Diabetes causes cardiac autonomic neuropathy, with remodelling and parasympathetic and sympathetic denervation, (132) thereby causing a direct effect on electrophysiological properties of atrial tissue.

Still, a dose-response effect has been demonstrated in a study by Dublin and co-workers 2010 in a population-based case-control study. (133) The AF risk was higher with longer duration of treated diabetes and worse glycaemic control. A dose-response effect is considered to support causality. Insulin resistance (IR) has been much studied, as this is associated with incident CHD and also with inflammation and obesity. Some studies have indicated that IR could be an underlying mechanism in the development of AF in patients with type 2 diabetes. (134) However, a report from Framingham 2012 did not observe an association between IR and incident AF. (135)

Diabetes is increasing in society, and the influence on AF development is thereby likely to increase.

7.3 Palpitations

Our main novel finding in paper 1 was the importance of self-reported palpitations, which were frequent in the total cohort, especially in women. The prevalence of palpitations varies in different populations, dependent on definitions and diagnostic methods. However, palpitations are a frequent symptom in the general population, and have been found to be the cause of presenting to a GP in 16 % of visits. (136)

Palpitations reported at baseline increased the risk of AF in women by 62% and in men by 91%. In our study, women reported more palpitations. This is similar to other studies. (72, 137) On the other hand, men who reported palpitations were more likely to be diagnosed with AF. It is interesting

to notice that the study from a GP setting in UK published in 2001 (137) also found that men presenting with palpitations were more likely (OR 2.1) to have a cardiac cause for their palpitations than did women.

What causes palpitations?

Aetiological causes are usually subdivided into five main groups: *cardiac arrhythmias, structural heart diseases, psychosomatic disorders, systemic diseases, and effects of drugs.* (71) Contractions of the heart which are too rapid, irregular or too slow will often (but not always) be registered as palpitations. Any type of tachyarrhythmia can give rise to palpitations, regardless of whether or not there is an underlying structural arrhythmogenic heart disease. Conditions associated with increased stroke volume, as in some structural heart diseases, and also in pregnancy, can cause palpitations. Also, the subjective perception of the heartbeat can be changed or anomalous in some individuals, thus causing an otherwise normal heart rhythm to be poorly tolerated, as in the case of some psychosomatic disorders.

Clinical studies have given conflicting information on the causes of palpitations, depending on the population studied. A much cited study from USA of 190 patients presenting in an emergency department or admitted to hospital because of palpitations, concluded that cardiac arrhythmias were diagnosed in 40%, psychosomatic in 30%, miscellaneous (systemic causes, structural heart disease, drugs) in 10%, and 16% remained unknown. (138) In a GP setting, only 19% had a clinically significant arrhythmia. (137) In a Norwegian study from a cardiac outpatient clinic, examining 198 consecutive patients with palpitations, a psychiatric/psychosomatic cause was diagnosed in 39%, CHD in 4%, while arrhythmias in need of treatment were not found. (139) Thus, palpitations can represent heterogeneous mechanisms, with highly different clinical implications.

Palpitations may indicate a predisposing substrate or early paroxysms of AF.

Premature atrial contractions (PACs) have been shown to precede AF (140, 141) and to be a surrogate marker for paroxysmal AF in patients with acute ischemic stroke. (142, 143) Excessive supraventricular ectopic activity in apparently healthy subjects was also associated with development of atrial fibrillation and with a poor prognosis in term of death or stroke, in a report from the Copenhagen Holter Study. (144)

A recent Swiss study found that PACs are common, as 99% of people over the age of 50 had at least one PAC on 24-hour Holter monitoring. The frequency of PACs is independently associated with age, history of cardiovascular disease, natriuretic peptide levels, physical activity and HDL cholesterol.

(145) Surprisingly, this study also found a significant association with body height and PACs. It has been hypothesised that tall individuals have larger atria, thereby increasing the risk for AF. This study could suggest that tall individuals also might have electrical alterations, making them prone to the development of AF. Of note, hypertension and BMI were not significantly related to PAC frequency. Although high blood pressure and obesity are two of the strongest risk factors for AF occurrence, this study might suggest that these two risk factors are exerting their effects via morphological means, but do not have much influence on the electrical part of AF.

Palpitations in our study:

The association between palpitations and AF raise two new questions.

Palpitations could be precursors of AF and basically caused by the same physiological and biochemical mechanisms, thereby also having common risk factors.

Or, palpitations are causally associated with atrial fibrillation (conditioning the atria), but caused by other factors than those associated with atrial fibrillation.

In order to investigate potential overlapping risk factors between palpitations and AF, we examined separately the predictors for palpitations and for AF (without including palpitations as a cofactor), in a cross-sectional logistic regression model. (Table 3.) We found that body height was a significant risk factor for both palpitations and AF. For palpitations, but not for AF, some significant risk factors were related to lifestyle (coffee, smoking). In contrast, the most prominent risk factors for atrial fibrillation were biological factors such as age, blood pressure, height, BMI, and for women also diabetes. Height, antihypertensive treatment and CHD were risk factors for both palpitations and atrial fibrillation. We therefore suggest that palpitations are probably causally associated with atrial fibrillation, but caused by other factors than those associated with atrial fibrillation.

The table also includes results when subjects with baseline CHD are excluded; this did not change the results.

Table 3. Risk factors for palpitations and AF, assessed separately

Risk factor	OR sign. (p)							
	Palpitations		Palpitations, baseline CHD excluded		AF		AF, baseline CHD excluded	
	Women	Men	Women	Men	Women	Men	Women	Men
Age (1 SD)	1.08 0.026	...	1.08 0.037	...	4.48 <0.0001	3.42 <0.0001	4.51 <0.0001	3.70 <0.0001
Systolic blood pressure (1 SD)	1.20 0.012	...	1.29 0.001	...
Heart rate (1 SD)	...	1.09 0.002	...	1.12 <0.0001
Height (1 SD)	1.14 0.001	1.12 0.003	1.15 <0.0001	1.13 0.004	1.30 0.040	1.37 <0.0001		1.19 <0.0001
Body mass index (1 SD)	1.27 <0.0001	1.59 <0.0001	1.24 0.003	1.52 <0.0001
Cholesterol (total) (1 SD)	...	1.09 0.011	...	1.08 0.021
HDL-cholesterol (1 SD)	0.92 0.027	...	1.21 0.004	...	1.10 0.001
Alcohol (1 SD)	...	1.08 <0.0001	...	1.09 <0.0001
Coffee (yes/no)	1.22 0.015	...	1.22 0.015
Smoking (yes/no)	1.19 0.001	1.36 <0.0001	1.20 <0.0001	1.34 <0.0001	...	0.76 0.037	...	0.72 0.030

Logistic regression model
Only significant results displayed

7.4 Inflammation

Inflammation has been shown in several studies to be associated with AF. (75-77) Whether inflammation is an initiator or a consequence or merely an association of AF is still debated. However, many studies support the concept that inflammation contributes to at least some types of AF. (76, 146)

When the Tromsø 4 survey was planned, around 1990, the attention towards inflammation as a risk factor for CVD was still only beginning to rise. Therefore, only a very limited selection of inflammatory biomarkers is available from this study: hs-CRP, OPG, WBC and fibrinogen. However, these biomarkers have been assessed in other studies, and we therefore wanted to make comparisons. (Paper 2.)

hs-CRP has proven to be a risk factor for cardiovascular disease in general, and also for AF in many studies. (76, 147) In our study, hs-CRP was associated with future AF in men. Other studies have reported hs-CRP to be an independent risk factor for future AF in both genders, although with varying strength of association. (75, 76) Most studies have not reported sex-specific analyses.

OPG has been increasingly studied as a marker of CVD. OPG is associated with inflammation, vascular calcification, endothelial function and atherosclerosis. OPG is also associated with diabetes, hypertension and obesity. (148) High plasma OPG is a strong predictor of CVD, ischemic stroke and total mortality, in high risk and general populations. (78) An association between OPG and AF could be linked via these conditions which are often co-existent with AF.

A study from the Framingham offspring cohort reported that a panel of 12 inflammatory markers predicted incident AF, but only OPG was significantly associated with AF. However, this relation lost its significance when myocardial infarction and heart failure were taken into account. (79) This appears to be in contrast with our study, as we found a significant association between OPG and AF in the total study population in the multivariable analysis, when excluding persons with pre-existing CHD or myocardial infarction. One could therefore speculate if a direct relation exists between OPG and AF in these CHD-healthy persons.

The level of **WBC** as a marker of future health outcomes in a general population has barely been investigated previously. We therefore wanted to study the impact of WBC on future AF. We found a significant increase in AF across quartiles of WBC in men, but not in women. Other publications on this topic seem to be lacking. However, several studies have reported the infiltration of WBC in the atria of AF patients, (74, 149) also in patients with lone AF without overt cardiovascular disease. The role of WBC in the development of AF remains undefined, but may promote structural and electrical remodelling by multiple mechanisms. These include the release of cytokines, and WBC are also an important source of reactive oxygen species (ROS) which stimulate fibroblasts.

Fibrinogen has been studied with conflicting results, but was found to predict future AF in the Copenhagen City Heart Study, (80) in the ARIC study (81) and the Women's Health Study. (77) A recent, large German study also reported that fibrinogen was significantly associated with AF in multivariable-adjusted models. (150) Others found no association between fibrinogen and future AF, (82, 83, 147) as was also the case in our study. The studies mentioned have been done in different age groups, and risk factor adjustment has also been performed differently. This could partly explain the apparently conflicting results.

The discussion of inflammation has been addressed thoroughly in paper 2.

7.5 Uric acid (UA)

An association between UA and future AF has been scarcely investigated until recent years. Whether UA is a cause of AF, or a confounder, is debated.

In paper 3, we found that baseline serum UA was associated with future AF, when adjusted for factors known to predispose for AF. The association was stronger in women than in men. Our results are partly in concordance with other studies. The first population-based prospective study to show an association between UA and future AF was published 2011 from the ARIC Study. (102) A recent meta-analysis by the same authors stated that high UA is associated with AF in both cross-sectional and cohort studies. (151) The relative risk of having AF for those with high UA was 1.67 (95% CI 1.23-2.27) compared with those with normal UA. A Japanese cross-sectional study published 2012 also found a relation between UA and AF in both genders, but the association after multivariable adjustments remained independent in women only. (103) The reason for this gender difference remains unexplained.

UA levels have also been shown to be associated with future AF in diabetic patients (152) and in patients with ischemic heart failure. (153)

UA is a marker of oxidative stress and a mediator of endothelial dysfunction, (154) and is associated with hypertension, CVD, obesity, inflammation, renal disease and diabetes. (155) All these conditions are known to represent risk factors for AF, and the association between UA and AF may therefore be linked through a number of ways. However, there is also evidence that UA is directly involved in the pathogenesis of these conditions. Elevated UA is a precursor of hypertension, and is known to activate the renin-angiotensin system. Clinical studies have shown that reducing UA with allopurinol (XO inhibitor) lowers blood pressure. (156) In CVD, treatment with allopurinol ameliorates angina. (157) Inflammation increases UA due to cell destruction. UA is therefore considered as a marker of inflammation. However, UA also activates pro-inflammatory cytokines and thereby promotes inflammation. (154, 158) Insulin reduces renal excretion of UA, however, hyperuricaemia often precedes the development of hyperinsulinaemia and diabetes, as well as obesity. (155)

A direct effect of UA on AF is also possible, and is supported by our study, as well as other studies mentioned above.

Population studies of UA have shown that mean levels in men increased gradually from the 1920s to the 1970s. (155) A recent analysis from USA (NHANES 2007-2008) showed that the prevalence of hyperuricaemia has increased substantially during the last decades. In this population with a mean

age of 47 years, 21% of both women and men had hyperuricaemia by definition. (98) In our study population with a mean age of 60 years, 15.3% of women had hyperuricaemia, and 12.7% of men ($> 350 \mu\text{mol/L}$ for women and $> 450 \mu\text{mol/L}$ for men).

In the NHANES study mentioned above, hyperuricaemia showed stronger associations with comorbidities among women than among men. It is suggested that the relative physiologic impact of hyperuricaemia may be stronger in women.

Thus, the prevalence of hyperuricaemia has increased substantially during the last decades. The associated comorbidities increase accordingly, with a corresponding impact on society's health cost.

7.6 Lone atrial fibrillation (Lone AF)

We wanted to focus on lone AF, which has been investigated incompletely previously (paper 1). This term was first introduced in 1953, referring to AF subjects in whom heart disease could not be demonstrated. During the last decades, as defined in the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation, the term "lone AF" generally applies to young individuals (under 60 years of age) without clinical or echocardiographic evidence of cardiopulmonary disease, including hypertension. (159) Hence, lone AF is a diagnosis of exclusion.

As expected, a low percentage in our study was found to have lone AF, as this applied to only 4.4% of the female and 7.2% of the male AF patients. In previous studies, the prevalence of lone AF has been estimated to 2-30 %. (160, 161) This is presumably due to large heterogeneity of the populations studied, and possibly insufficient information about concomitant disease.

In our study population, 67% of lone AF patients were male. This is in concordance with other studies, which have found the male preponderance to be 70-80 %. (160)

Individuals with lone AF have been reported to be taller and leaner than other AF patients. In our study, men with lone AF were tall, but not lean. We also found a significant relation between BMI and lone AF in men. To our knowledge, this has not been shown earlier.

We also found that height was a risk factor for lone AF in men. Women with lone AF seemed to be taller and leaner (than AF women in general), but probably due to a low number in this group (n=16), these differences were not significant.

Premature atrial contractions (PACs) have been shown to increase the risk of AF and stroke.

A study from Switzerland 2012 found that PACs were associated with body height. (145) Tall individuals are presumed to have larger atria, thereby increasing the risk for AF. This Swiss study could suggest that tall individuals also might have electrical alterations, thereby increasing the risk for development of AF. One may speculate that this could play a role in cases of lone AF.

High-impact physical activity has been found to be associated with AF, especially lone AF type. In our study population, too few participants reported such level of activity, and we are not able to draw any conclusions in this field.

Our subgroup of lone AF is small, and conclusions are therefore uncertain. Moreover, in our analyses of lone AF, we lacked information about some risk factors for AF, such as pulmonary disease, obstructive sleep apnea, peripheral artery disease, chronic kidney disease, and inflammation. The exclusion of cardiac diseases in this group is based on data from their medical records, but echocardiography had not been performed. It is therefore possible that our group is not completely “pure”, but may contain persons with concomitant or subclinical disease.

As already mentioned, lone AF has previously been considered to occur in healthy individuals without identifiable risk factors. Whether lone AF really exists, or depends on how hard one looks for concomitant conditions, has been much debated. Growing insight into the diversity of numerous mechanisms involved in the pathogenesis of AF suggests that apparently lone AF might not be so “lone” in many patients. Atrial stretch, inflammation and oxidative stress have all been demonstrated in young individuals with presumed lone AF. (162) A genetic predisposition is likely and appears to play a stronger part in lone AF than in AF in general. Population studies have shown familial clustering of AF in young and heart-healthy individuals. Studies have also demonstrated several gene variants which are associated with lone AF. (163, 164)

The increasing evidence that even “lone” AF is associated with changes in cardiac structure and function, makes the lone AF term less meaningful. However, these patients have shown to have a lower risk for thromboembolism and mortality, and therefore do not require the same anticoagulant treatment as older patients with comorbid conditions. Yet, they need regular follow-up to assess any new risk factors presenting.

7.7 Gender differences

The words “sex” and “gender” are commonly used interchangeably in epidemiology. Other medical, psychological and social research fields distinguish between “sex” as the biological characteristic and “gender” as a social and cultural concept.

For many years, women were underrepresented in many medical studies. Therefore, they provided very few endpoints, e.g. in the cardiovascular field. As a result of this, the knowledge of diseases and their frequencies and clinical courses in women has been poorly acknowledged or understood. This is also the case for treatment strategies and the effects of pharmacologic intervention.

The last couple of decades have provided increasing evidence that male and female hearts are different in many aspects. The differences may be subtle, sometimes without clinical consequences, but in other connections of significance. As an example of this, many cardiovascular drugs have been found to have somewhat different therapeutic and adverse effects in men and women. (165) Women have a higher resting heart rate and a shorter sinus node recovery time. Women have longer QT interval and are more susceptible to ‘torsade de pointes’- arrhythmia when administered certain anti-arrhythmic drugs.

However, a reason why women should be less prone to AF, remains unknown.

Many studies have found that risk factors for AF are differently distributed in women and men, and that the risk factors show various strength of association in the two genders. However, these differences have not been fully consistent through the studies. This could be explained by differences in the populations studied, and that adjustment for confounders has been done differently. The adjustment for gender as a confounder is important, but often not sufficient.

Women with AF have demonstrated a poorer outcome than do men. Women have higher cardiovascular and all-cause mortality, as demonstrated in the large population studies of Framingham and Renfrew/Paisley. (166, 167) Studies have also shown that women have higher risk of AF-related stroke, (36, 167) and strokes are more severe in women, with poorer outcome. Women with AF report symptoms, palpitations included, to a larger extent than do men, and experience a lower quality of life. (35, 168, 169)

In our analyses, we found different strengths of association in women and men for many of the variables analysed. This has been discussed previously in this thesis, in the passages concerning the different risk factors, and will only be briefly mentioned here:

Hypertension, diabetes and uric acid are stronger risk factors for AF in women.

CHD and overweight are stronger risk factors for men. Inflammation may be of greater importance in men, as we found the biomarkers hs-CRP and WBC to be associated with future AF in men only.

Palpitations, although more frequent in women, was a stronger risk factor for AF in men in our study.

8. CONCLUSIONS

In this large, general Norwegian population from the Tromsø Study, we have shown that AF is more frequent than what has been assumed formerly, as 2.2% of women and 3.3% of men in our study were diagnosed with AF.

A main new finding was the importance of self-reported palpitations as a risk factor for AF, which has not been shown earlier. We confirmed that hypertension, overweight, diabetes and CHD were important risk factors. This is in accordance with other studies.

Among the four available inflammatory biomarkers, we found a significant increase in AF across quartiles of WBC. This has not been shown earlier. hs-CRP was associated with AF in men. OPG was associated with AF in persons without CHD. Fibrinogen showed no association with AF in our study population.

Uric acid was a strong risk factor for AF.

Our study has confirmed the need for sex-specific analyses in medical research. We found different strength of associations in women and men for several variables.

Palpitations showed a stronger association with AF in men, although this symptom is more frequent in women.

Hypertension, diabetes and uric acid were stronger risk factors for AF in women.

CHD and overweight were stronger risk factors in men. Inflammation may be of greater importance in men.

Low physical activity, vigorous exercise, smoking and use of alcohol showed no association with AF in this population.

9. IMPLICATIONS

AF is a common arrhythmia, conferring considerable morbidity with the consequent need for medical care. AF occurrence has increased during the last decades, and is expected to rise further, with a rising proportion of the older population, and improved and prolonged survival from previously fatal cardiovascular conditions.

The investigation of risk factors is important, with the purpose to identify those that are potentially modifiable.

Still, the question remains whether correcting risk factors reduce AF risk. From clinical studies we now have evidence that weight loss reduces AF burden and severity. (128) Treatment of hypertension has proved favourable in other areas, e.g. in prevention of heart failure and stroke. A favourable effect in prevention of AF can therefore be expected. The prevention and treatment of cardiac disease in general is equally important, as is the prevention of diabetes and overweight.

The importance of inflammatory states is still not conclusive, and needs further research.

The association of uric acid and future AF is interesting and intriguing, and raises the question whether treatment with uric acid lowering agents could reduce the risk for AF. This should be investigated in clinical studies.

Updated endpoints (1994-2012) for our study population are now available. Re-analyses of data are therefore possible and interesting, to address any stronger or other associations.

Other variables are also available and now under research.

References

1. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-- a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2012;14(1):8-27.
2. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ Arrhythm Electrophysiol*. 2008;1(1):62-73.
3. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest*. 2011;121(8):2955-68.
4. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res*. 2014;114(9):1500-15.
5. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet*. 2009;373(9658):155-66.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke; a journal of cerebral circulation*. 1991;22(8):983-8.
7. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol*. 1998;82(8A):2N-9N.
8. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. *Stroke; a journal of cerebral circulation*. 1996;27(10):1765-9.
9. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? *Stroke; a journal of cerebral circulation*. 2005;36(2):360-6.
10. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. *Eur Heart J*. 2010;31(8):967-75.
11. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J*. 2015;36(5):281-7a.
12. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *Eur Heart J*. 2015;36(5):288-96.
13. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. *Stroke; a journal of cerebral circulation*. 1997;28(2):316-21.
14. Dublin S, Anderson ML, Haneuse SJ, Heckbert SR, Crane PK, Breitner JC, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. *J Am Geriatr Soc*. 2011;59(8):1369-75.
15. Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. *Heart Rhythm*. 2012;9(11):1761-8.
16. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. *J Am Coll Cardiol*. 2013;62(21):1990-7.

17. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med.* 1995;98(5):476-84.
18. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. *Med Clin North Am.* 2008;92(1):17-40, ix.
19. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. *Circulation.* 2014;129(3):e28-e292.
20. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med.* 2014;174(1):107-14.
21. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ Cardiovasc Qual Outcomes.* 2011;4(3):313-20.
22. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama.* 2001;285(18):2370-5.
23. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation.* 2006;114(2):119-25.
24. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. *International journal of cardiology.* 2013.
25. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. *Arch Intern Med.* 1995;155(5):469-73.
26. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *American heart journal.* 2009;158(1):111-7.
27. Mathur R, Pollara E, Hull S, Schofield P, Ashworth M, Robson J. Ethnicity and stroke risk in patients with atrial fibrillation. *Heart.* 2013;99(15):1087-92.
28. Rader F, Van Wagoner DR, Ellinor PT, Gillinov AM, Chung MK, Costantini O, et al. Influence of race on atrial fibrillation after cardiac surgery. *Circ Arrhythm Electrophysiol.* 2011;4(5):644-52.
29. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2013;15(4):486-93.
30. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. *Circ Cardiovasc Qual Outcomes.* 2012;5(1):85-93.
31. Chamberlain AM, Gersh BJ, Alonso A, Chen LY, Berardi C, Manemann SM, et al. Decade-long trends in atrial fibrillation incidence and survival: a community study. *Am J Med.* 2015;128(3):260-7 e1.
32. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. *American heart journal.* 1996;131(4):790-5.

33. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J*. 2006;27(8):949-53.
34. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet*. 2015;386(9989):154-62.
35. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation*. 2001;103(19):2365-70.
36. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Levy S, Cobbe S, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol*. 2007;49(5):572-7.
37. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *Jama*. 1994;271(11):840-4.
38. Fox CS, Parise H, D'Agostino RB, Sr., Lloyd-Jones DM, Vasani RS, Wang TJ, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. *Jama*. 2004;291(23):2851-5.
39. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. *Human genetics*. 2005;118(2):179-84.
40. Olesen MS, Andreassen L, Jabbari J, Refsgaard L, Haunso S, Olesen SP, et al. Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation. *Heart Rhythm*. 2014;11(2):246-51.
41. Mahida S, Ellinor PT. New advances in the genetic basis of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012;23(12):1400-6.
42. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G, et al. A sequence variant in ZFX3 on 16q22 associates with atrial fibrillation and ischemic stroke. *Nature genetics*. 2009;41(8):876-8.
43. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation*. 1997;96(7):2455-61.
44. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. *Am J Cardiol*. 2003;91(10A):9G-14G.
45. Madu EC, Baugh DS, Gbadebo TD, Dhala A, Cardoso S, Phi-Res Multi-Study G. Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging. *Clin Cardiol*. 2001;24(9):597-602.
46. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2008;10(2):238-41.
47. Wachtell K, Lehto M, Gerds E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol*. 2005;45(5):712-9.
48. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. *Eur Heart J*. 2006;27(5):512-8.

49. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. *Eur J Epidemiol.* 2010;25(2):95-102.
50. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. *American heart journal.* 2008;156(6):1163-9.
51. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. *Heart Rhythm.* 2011;8(8):1160-6.
52. Ettinger PO, Wu CF, De La Cruz C, Jr., Weisse AB, Ahmed SS, Regan TJ. Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. *American heart journal.* 1978;95(5):555-62.
53. Djousse L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. *Am J Cardiol.* 2004;93(6):710-3.
54. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. *Arch Intern Med.* 2004;164(18):1993-8.
55. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. *Jama.* 2008;300(21):2489-96.
56. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y, et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. *J Am Coll Cardiol.* 2011;57(4):427-36.
57. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Clin Nutr.* 2005;81(3):578-82.
58. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. *Am J Clin Nutr.* 2010;92(3):509-14.
59. Gronroos NN, Alonso A. Diet and risk of atrial fibrillation - epidemiologic and clinical evidence. *Circ J.* 2010;74(10):2029-38.
60. Khawaja O, Gaziano JM, Djousse L. A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation. *J Am Coll Nutr.* 2012;31(1):4-13.
61. Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association.* 2013;2(1):e005033.
62. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2008;10(1):15-20.
63. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2009;11(9):1156-9.
64. Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors--a 28-30 years follow-up study. *Eur J Cardiovasc Prev Rehabil.* 2010;17(1):100-5.
65. Graff-Iversen S, Gjesdal K, Jugessur A, Myrstad M, Nystad W, Selmer R, et al. Atrial fibrillation, physical activity and endurance training. *Tidsskr Nor Laegeforen.* 2012;132(3):295-9.

66. Wang TJ, Parise H, Levy D, D'Agostino RB, Sr., Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. *Jama*. 2004;292(20):2471-7.
67. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Med*. 2005;118(5):489-95.
68. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, et al. Risk of new-onset atrial fibrillation in relation to body mass index. *Arch Intern Med*. 2006;166(21):2322-8.
69. Abed HS, Wittert GA. Obesity and atrial fibrillation. *Obes Rev*. 2013;14(11):929-38.
70. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. *Diabetes care*. 2009;32(10):1851-6.
71. Raviele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L, et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2011;13(7):920-34.
72. Lochen ML. The Tromso Study: associations between self-reported arrhythmia, psychological conditions, and lifestyle. *Scand J Prim Health Care*. 1991;9(4):265-70.
73. Lochen ML, Snarud T, Zhang W, Rasmussen K. Arrhythmias in subjects with and without a history of palpitations: the Tromso Study. *Eur Heart J*. 1994;15(3):345-9.
74. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation*. 1997;96(4):1180-4.
75. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? *Eur Heart J*. 2006;27(2):136-49.
76. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation*. 2003;108(24):3006-10.
77. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. *Eur Heart J*. 2010;31(14):1730-6.
78. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. *J Thromb Haemost*. 2011;9(4):638-44.
79. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. *Am J Cardiol*. 2009;104(1):92-6.
80. Mukamal KJ, Tolstrup JS, Friberg J, Gronbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). *Am J Cardiol*. 2006;98(1):75-81.
81. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. *International journal of cardiology*. 2012;155(2):217-22.
82. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. *Stroke; a journal of cerebral circulation*. 2003;34(2):413-7.
83. Adamsson Eryd S, Smith JG, Melander O, Hedblad B, Engstrom G. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. *Eur J Epidemiol*. 2011;26(6):449-55.

84. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. *Jama*. 2000;283(18):2404-10.
85. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med*. 2004;164(14):1546-51.
86. Strasak AM, Kelleher CC, Brant LJ, Rapp K, Ruttman E, Concini H, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. *International journal of cardiology*. 2008;125(2):232-9.
87. Storhaug HM, Norvik JV, Toft I, Eriksen BO, Lochen ML, Zykova S, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. *BMC Cardiovasc Disord*. 2013;13:115.
88. Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. *Eur J Neurol*. 2002;9(3):221-6.
89. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. *Am J Epidemiol*. 2009;169(9):1064-9.
90. Shen L, Ji HF. Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis. *BMJ Open*. 2013;3(11):e003620.
91. Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. *J Neurol*. 2012;259(9):1923-8.
92. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. *Brain*. 2009;132(Pt 2):377-82.
93. Verhaaren BF, Vernooij MW, Dehghan A, Vrooman HA, de Boer R, Hofman A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. *Neuroepidemiology*. 2013;41(1):29-34.
94. Hong JY, Lan TY, Tang GJ, Tang CH, Chen TJ, Lin HY. Gout and the risk of dementia: a nationwide population-based cohort study. *Arthritis Res Ther*. 2015;17:139.
95. Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. *Ann Rheum Dis*. 2015.
96. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. *Arthritis Rheum*. 2010;62(4):1069-76.
97. Høiegggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney Int*. 2004;65(3):1041-9.
98. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. *Am J Med*. 2012;125(7):679-87 e1.
99. Kivity S, Kopel E, Maor E, Abu-Bachar F, Segev S, Sidi Y, et al. Association of serum uric acid and cardiovascular disease in healthy adults. *Am J Cardiol*. 2013;111(8):1146-51.
100. Kivity S, Kopel E, Steinlauf S, Segev S, Sidi Y, Olchovsky D. The association between serum uric acid and diabetes mellitus is stronger in women. *J Womens Health (Larchmt)*. 2013;22(9):782-9.
101. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, et al. Uric acid elevation in atrial fibrillation. *Hellenic J Cardiol*. 2010;51(3):209-13.

102. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, et al. Association of Serum Uric Acid With Incident Atrial Fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). *Am J Cardiol.* 2011;108(9):1272-6.
103. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, et al. Gender-specific relationship between serum uric Acid level and atrial fibrillation prevalence. *Circ J.* 2012;76(3):607-11.
104. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromsø Study. *Int J Epidemiol.* 2012;41(4):961-7.
105. Rosengren A, Wilhelmsen L, Berglund G, Elmfeldt D. Non-participants in a general population study of men, with special reference to social and alcoholic problems. *Acta Med Scand.* 1987;221(3):243-51.
106. Jacobsen BK, Thelle DS. The Tromsø Heart Study: responders and non-responders to a health questionnaire, do they differ? *Scand J Soc Med.* 1988;16(2):101-4.
107. Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Med Res Methodol.* 2012;12:143.
108. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. *Am J Med.* 2015;128(5):509-18 e2.
109. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. *Br J Gen Pract.* 1997;47(418):285-9.
110. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. *Circulation.* 2004;109(18):2175-80.
111. Perez de Ciriza C, Lawrie A, Varo N. Influence of pre-analytical and analytical factors on osteoprotegerin measurements. *Clin Biochem.* 2014;47(13-14):1279-85.
112. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kario K, Ito Y, et al. Comparison of C-reactive protein levels between serum and plasma samples on long-term frozen storage after a 13.8 year interval: the JMS Cohort Study. *J Epidemiol.* 2007;17(4):120-4.
113. Tveit A, Abdelnoor M, Enger S, Smith P. Atrial fibrillation and antithrombotic therapy in a 75-year-old population. *Cardiology.* 2008;109(4):258-62.
114. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2011;13(8):1110-7.
115. Management AIAFF-uIoR. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. *American heart journal.* 2002;143(6):991-1001.
116. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. *Circ J.* 2011;75(12):2767-74.
117. Lopez FL, Agarwal SK, Maclellan RF, Soliman EZ, Sharrett AR, Huxley RR, et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. *Circ Arrhythm Electrophysiol.* 2012;5(1):155-62.
118. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *BMJ.* 2011;342:d1250.
119. Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. *Eur Heart J.* 2009;30(9):1113-20.

120. Guenancia C, Stamboul K, Garnier F, Beer JC, Touzery C, Lorgis L, et al. Obesity and new-onset atrial fibrillation in acute myocardial infarction: a gender specific risk factor. *International journal of cardiology*. 2014;176(3):1039-41.
121. Filardo G, Hamilton C, Hamman B, Hebel RF, Jr., Grayburn PA. Relation of obesity to atrial fibrillation after isolated coronary artery bypass grafting. *Am J Cardiol*. 2009;103(5):663-6.
122. Thanassoulis G, Massaro JM, O'Donnell CJ, Hoffmann U, Levy D, Ellinor PT, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. *Circ Arrhythm Electrophysiol*. 2010;3(4):345-50.
123. Gerds E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Hypertension*. 2002;39(3):739-43.
124. Tiwari S, Schirmer H, Jacobsen BK, Hopstock LA, Nyenes A, Heggelund G, et al. Association between diastolic dysfunction and future atrial fibrillation in the Tromso Study from 1994 to 2010. *Heart*. 2015.
125. Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. *Am J Cardiol*. 2006;98(1):116-20.
126. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. *J Am Coll Cardiol*. 2011;57(12):1368-74.
127. Karasoy D, Bo Jensen T, Hansen ML, Schmiegelow M, Lamberts M, Gislason GH, et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2013;15(6):781-6.
128. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *Jama*. 2013;310(19):2050-60.
129. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol*. 2011;108(1):56-62.
130. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. *Circulation*. 2003;107(3):448-54.
131. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. *Circulation*. 2007;115(25):3213-23.
132. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. *Int Heart J*. 2009;50(5):627-41.
133. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med*. 2010;25(8):853-8.
134. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. *Diabetes Obes Metab*. 2004;6(5):367-74.
135. Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). *Am J Cardiol*. 2012;109(1):87-90.

136. Barsky AJ, Ahern DK, Bailey ED, Delamater BA. Predictors of persistent palpitations and continued medical utilization. *J Fam Pract.* 1996;42(5):465-72.
137. Summerton N, Mann S, Rigby A, Petkar S, Dhawan J. New-onset palpitations in general practice: assessing the discriminant value of items within the clinical history. *Fam Pract.* 2001;18(4):383-92.
138. Weber BE, Kapoor WN. Evaluation and outcomes of patients with palpitations. *Am J Med.* 1996;100(2):138-48.
139. Jonsbu E, Dammen T, Morken G, Lied A, Vik-Mo H, Martinsen EW. Cardiac and psychiatric diagnoses among patients referred for chest pain and palpitations. *Scand Cardiovasc J.* 2009;43(4):256-9.
140. Bennett MA, Pentecost BL. The pattern of onset and spontaneous cessation of atrial fibrillation in man. *Circulation.* 1970;41(6):981-8.
141. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med.* 1998;339(10):659-66.
142. Wallmann D, Tuller D, Kucher N, Fuhrer J, Arnold M, Delacretaz E. Frequent atrial premature contractions as a surrogate marker for paroxysmal atrial fibrillation in patients with acute ischaemic stroke. *Heart.* 2003;89(10):1247-8.
143. Wallmann D, Tuller D, Wustmann K, Meier P, Isenegger J, Arnold M, et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. *Stroke; a journal of cerebral circulation.* 2007;38(8):2292-4.
144. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. *Circulation.* 2010;121(17):1904-11.
145. Conen D, Adam M, Roche F, Barthelemy JC, Felber Dietrich D, Imboden M, et al. Premature atrial contractions in the general population: frequency and risk factors. *Circulation.* 2012;126(19):2302-8.
146. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. *J Am Coll Cardiol.* 2007;50(21):2021-8.
147. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. *Circulation.* 2010;121(2):200-7.
148. Perez de Ciriza C, Lawrie A, Varo N. Osteoprotegerin in Cardiometabolic Disorders. *Int J Endocrinol.* 2015;2015:564934.
149. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. *Am J Cardiol.* 2008;102(7):861-5.
150. Schnabel RB, Wild PS, Wilde S, Ojeda FM, Schulz A, Zeller T, et al. Multiple biomarkers and atrial fibrillation in the general population. *PLoS One.* 2014;9(11):e112486.
151. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. *Heart Rhythm.* 2014;11(7):1102-8.
152. Valbusa F, Bertolini L, Bonapace S, Zenari L, Zoppini G, Arcaro G, et al. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. *Am J Cardiol.* 2013;112(4):499-504.
153. Tekin G, Tekin YK, Erbay AR, Turhan H, Yetkin E. Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. *Angiology.* 2013;64(4):300-3.

154. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. *Semin Nephrol.* 2005;25(1):39-42.
155. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med.* 2008;359(17):1811-21.
156. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *Jama.* 2008;300(8):924-32.
157. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. *Lancet.* 2010;375(9732):2161-7.
158. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ, et al. Hormonal and cytokine effects of uric acid. *Curr Opin Nephrol Hypertens.* 2006;15(1):30-3.
159. Fuster V, Ryden LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation.* 2006;114(7):e257-354.
160. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation.* 2007;115(24):3050-6.
161. Taggar JS, Lip GY. Risk predictors for lone atrial fibrillation. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2008;10(1):6-8.
162. Potpara TS, Lip GY. Lone atrial fibrillation - an overview. *Int J Clin Pract.* 2014;68(4):418-33.
163. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. *Nature genetics.* 2010;42(3):240-4.
164. Olesen MS, Holst AG, Jabbari J, Nielsen JB, Christophersen IE, Sajadieh A, et al. Genetic loci on chromosomes 4q25, 7p31, and 12p12 are associated with onset of lone atrial fibrillation before the age of 40 years. *Can J Cardiol.* 2012;28(2):191-5.
165. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. *Handb Exp Pharmacol.* 2012(214):211-36.
166. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation.* 1998;98(10):946-52.
167. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med.* 2002;113(5):359-64.
168. Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. *Am J Cardiol.* 2000;86(7):764-8.
169. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. *American heart journal.* 2006;152(6):1097-103.